$SDGR Income Statement | Understand Stock

$SDGR

$26.72 +$2.22 (9.06%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenues
Software products and services
Drug discovery
Total revenues
Cost of revenues:
Software products and services
Drug discovery
Total cost of revenues
Gross profit
Operating expenses:
Research and development
Sales and marketing
General and administrative
Total operating expenses
Loss from operations
Other income:
Gain on equity investments
Interest income
Change in fair value of equity investments
Other income
Total other income
(Loss) income before income taxes

Income tax expense
Consolidated net income (loss)
Net income (loss) attributable to noncontrolling interest
Net (loss) income
Net loss per share attributable to Schrödinger common and limited common stockholders, basic and diluted:
Weighted average shares used to compute net loss per share attributable to Schrödinger common and limited common stockholders, basic and diluted:
Net (loss) income per share attributable to common and limited common stockholders, basic (in USD per share)
Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, basic (in shares)
Net (loss) income per share of common and limited common stockholders, diluted (in USD per share)
Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted (in shares)

Comments